Anakinra, a recombinant human antagonist of IL-1 (blocking both IL-1α and IL-1β) and lutikizumab (a dual-variable-domain IL 1α/1β antagonist) have shown some promise for the treatment of HS (13, 60). The gene discussed is IL1A; the disease is histiocytic sarcoma.